Dublin, Oct. 24, 2022 (GLOBE NEWSWIRE) -- The "Drug Eluting Balloon Market, by Product Type, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
Drug eluting balloons are angioplasty balloons that are coated with an anti-proliferative drug, which is eluted in vessel walls during the inflation of balloon, usually at nominal pressure with a specific minimal inflation time. The active substance coated on the drug eluting balloon should be lipophilic in nature to have a high absorption rate through the vessel wall.
Mostly paclitaxel is used as active ingredient due to its high pharmacokinetic transfer rate into the vessel wall and it is actively used in drug eluting balloons in the U.S. market and has been already approved for use in Europe. Drug-coated balloons (DCB), also referred to as drug-eluting balloons (DEB), were created as a way to reduce very high restenosis rates in peripheral vessels. They also have been investigated in clinical trials to prevent coronary artery in-stent restenosis. The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded.
The drug helps prevent neointimal hyperplasia (scar tissue growth) caused by trauma when the vessel segment is treated for atherosclerotic lesions with balloon angioplasty. DCBs can be used to treat hyperplasia in arteriovenous (AV) access fistulae in dialysis patients, where the vessel undergoes repeated trauma from regular punctures. DCBs are also used to treat in-stent restenosis due to scar tissue proliferation inside stents, which can cause a vessel to occlude. Angioplasty using percutaneous coronary intervention techniques revealed satisfying result compared to conservative medical treatment.
Market Dynamics
Increasing product launches by key players in market are expected to drive the global drug eluting balloon market growth. For instance, in October 2019, Koninklijke Philips N.V., a health technology company, launched two new Stellarex Drug-Coated Balloon Sizes. Royal Philips introduced two new balloons to its Stellarex 0.035" low-dose drug-coated balloon (DCB) portfolio.
The new 200mm and 150mm Stellarex 0.035" low-dose DCBs have received approval from the U.S. Food and Drug Administration (FDA) for the treatment of de novo and restenotic lesions in native superficial femoral or popliteal arteries, both arteries in the upper leg. The new balloons broadened physicians' treatment options for peripheral artery disease (PAD) patients with a high risk of restenosis and expand the Stellarex portfolio.
Key features of the study:
- This report provides an in-depth analysis of the global drug eluting balloon market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global drug eluting balloon market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Medtronic, Becton, Dickinson and Company (BD), Boston Scientific Corporation, Cook Medical, B. Braun Melsungen AG, Koninklijke Philips N.V., Opto Circuits (India) Limited, Terumo Corporation, Surmodics, Inc., and Biotronik.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global drug eluting balloon market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global drug eluting balloon market
Detailed Segmentation:
Global Drug Eluting Balloon Market, By Product Type:
- Coronary Drug Eluting Balloon
- Peripheral Drug Eluting Balloon
- Others
Global Drug Eluting Balloon Market, By End User:
- Hospitals
- CATH Laboratories
- Ambulatory Surgical Centres
- Others
Global Drug Eluting Balloon Market, By Region:
- North America
- By Country
- U.S.
- Canada
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Region
- South Africa
- Central Africa
- North Africa
Key Topics Covered:
1. Research Objectives and Assumptions
2. Market Purview
3. Market Dynamics, Regulations, and Trends Analysis
4. Global Drug Eluting Balloon Market- Impact of Coronavirus (Covid-19) Pandemic
5. Global Drug Eluting Balloon Market, By Product Type, 2017 - 2030, (US$ Million)
6. Global Drug Eluting Balloon Market, By End User, 2017 - 2030, (US$ Million)
7. Global Drug Eluting Balloon Market, By Region, 2017 - 2030, (US$ Million)
8. Competitive Landscape
9. Section
Companies Mentioned
- Medtronic
- Becton, Dickinson and Company
- Boston Scientific Corporation
- Cook Medical
- Braun Melsungen AG
- Koninklijke Philips N.V.
- Opto Circuits (India) Limited
- Terumo Corporation
- Surmodics, Inc.
- Biotronik
For more information about this report visit https://www.researchandmarkets.com/r/pj6vc6
